Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

NCT02234310 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia B

Interventions

BIOLOGICAL: rFIXFc

Sponsor

Bioverativ, a Sanofi company

Collaborators

[object Object]